This page was reviewed under our medical and editorial policy by
Toufic Kachaamy, MD, Chief of Medicine, City of Hope Phoenix
This page was updated on May 26, 2023.
Pancreatic cancer accounts for approximately 3 percent of all cancers in the United States. In 2024, about 66,440 people will be diagnosed with pancreatic cancer (34,530 men and 31,910 women), according to the American Cancer Society (ACS). Accurately diagnosing pancreatic cancer often requires different types of tests.
The care team will likely consist of a:
The team may use blood tests, imaging tests, biopsies and possibly molecular testing to obtain as complete a picture as possible. This process also helps doctors identify appropriate treatment options.
It’s challenging to detect pancreatic cancer early because there’s currently no standard diagnostic screening test for patients at average risk. For those with an above-average risk—such as those who have a family history of pancreatic cancer or a diagnosed genetic syndrome known to raise their predisposition, doctors may use screening tools such as an endoscopic ultrasound or magnetic resonance imaging (MRI).
Additionally, the pancreas is located so deep inside the body that it’s extremely difficult for doctors to palpate (feel) any tumors (and even the pancreas itself) during a physical examination.
However, it’s possible that pancreatic cancer may cause early symptoms, or that testing for other medical conditions may show signs of pancreatic cancer, causing the care team to diagnose it early. Most often, symptoms aren’t apparent in early stages, and small lesions aren’t always detected by pancreatic cancer diagnostic tests, so cases tend to be diagnosed in more advanced stages.
Blood tests may provide clues that indicate the presence of the disease, but they don’t provide definitive early detection of pancreatic cancer. Blood tests help the care team determine whether further testing is warranted. They include:
The first sign of pancreatic cancer may be jaundice, which causes yellowing of the whites of the eyes and the skin. When a patient has jaundice, the doctor will typically order liver function tests to find out what’s causing it to occur. These blood tests measure levels of bilirubin, a chemical produced by the liver, as well as of liver enzymes in the blood, in order to differentiate between jaundice caused by liver disease and other issues. High levels of bilirubin present in the blood may indicate pancreatic cancer.
Tumor markers are substances released into the body by a tumor. Identifying these substances, or biomarkers, can assist with the diagnosis of pancreatic cancer:
Carbohydrate antigen 19-9 (CA19-9): Even healthy people have some CA 19-9 protein in their blood, but elevated levels of this marker may indicate pancreatic cancer.
Carcinoembryonic antigen (CEA): Some noncancerous conditions may cause high CEA levels (such as rectal polyps or cirrhosis), but elevated CEA levels may also indicate pancreatic cancer.
Not all people with elevated levels of these tumor markers have pancreatic cancer, and not all people with pancreatic cancer will have elevated levels. Patients with pancreatic cancer and high levels of these markers may be asked to undergo repeated blood tests to evaluate whether the treatment is working.
Imaging screenings provide a visual snapshot of the pancreas to expose potential abnormalities. The type of tests used may depend on each patient's situation and symptoms.
Tests may include:
A biopsy tests suspicious tissue for signs of cancer and is an important part of the diagnostic process. A tissue sample is taken, either during one of the endoscopic imaging procedures or with a needle biopsy (in which a fine needle is inserted into the pancreas to retrieve cells), then sent to a pathologist who studies it under a microscope.
If other tests indicate a high likelihood that a tumor is cancerous, the patient may undergo surgery to have it removed. In this case, the tissue may be analyzed after surgery, instead of through a biopsy.
The care team may recommend molecular testing or genetic testing for pancreatic cancer to help make more personalized decisions about treatments like immunotherapy or targeted therapy.
Genetic testing uses a saliva or blood sample to evaluate changes in cells called germline mutations to help guide treatment decisions.
Advanced genomic testing is a more sophisticated analysis of tissue and cell samples, looking for specific gene mutations or proteins that may help direct treatment.
Patients should ask their care teams whether these tests might be an option for them.
Reviewing test results enables the care team to put together a more complete picture of each patient's condition, including the stage of the cancer and treatment options.
Determining the stage of pancreatic cancer is based on three important factors: